The Biopsychosocial Impact of Mepolizumab in Severe Eosinophilic Asthma on Quantitative and Qualitative Emotional and Affective Outcomes in Patients and Partners
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).
⁃ Phase 1:
• Age 18 or over
• Having a diagnosis of severe eosinophilic asthma
• Currently on mepolizumab (Nucala®) treatment
• At least basic command of English
• Giving written informed consent
⁃ Phase 2 Patient eligibility Inclusion criteria
• Age 18 or over
• Having a diagnosis of severe eosinophilic asthma
• Scheduled to start mepolizumab (Nucala®) treatment
• At least basic command of English (for sub-study: conversational level of English that does not require a translator)
• Giving written informed consent
• Co-habiting with an intimate partner who is willing to participate in the study